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Methods: Retrospective analysis of chronic pancreatitis
patients in Healthcare Cost and Utilization Project Florida
State Inpatient Database 2007–2011 using revisit variables.
Patients with malignancy or congenital abnormalities
excluded. Surgical interventions and complications of
chronic pancreatitis identified using ICD-9 codes. Univariate
analysis of sex, Elixhauser score, race, insurance, complica-
tions, receipt of surgery by chi-square. Number of readmis-
sions, time to surgery by Wilcoxon rank sum. Multivariate
analysis of operative management by logistic regression.
Results: 21,448 chronic pancreatitis patients. 6.18% (1,325)
underwent surgery including 629 with drainage procedures,
275 with pancreatectomies, 735 with cholecystectomies.
Procedures decreased from 8.65% in 2007 to 3.10% in 2011
(p < 0.0001). 12.95% (2,778) developed pancreatitis-related
complications: pancreatic cysts or pseudocysts (4.40%), dia-
betes (10.02%). Pancreatic exocrine insufficiency in <11
patients. Median number of readmissions 1 (IQR 0–4) and 5
(IQR 2–9) among non-surgical and surgical patients, respec-
tively (p < 0.001). Median number of admissions prior to
pancreatectomy was 2 (IQR 1–4) and drainage procedure
was 2 (IQR 1–6). Predictors of surgical intervention dis-
played in table.
Conclusions: Chronic pancreatitis leads to numerous inpa-
tient readmissions and difficult to manage complications.
Surgical intervention occurs in a declining minority of cases.
Complicated patients are more likely to undergo surgery;
operative patients experience more admissions than
nonoperative patients. The complexities of chronic pancrea-
titis management warrant early multidisciplinary evaluation
and ongoing consideration of surgical and nonsurgical
options.
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LO-E.01 NEOADJUVANT
CHEMOTHERAPY DOES NOT IMPAIR
LIVER REGENERATION FOLLOWING
MAJOR HEPATECTOMY OR PORTAL
VEIN EMBOLIZATION FOR
COLORECTAL LIVER METASTASES
E. Simoneau1, N. Molla1, R. Alanazi2, J. Alshenaifi2,
M. Aljiffry3, A. Medkhaly2, L. Boucher1, P. Metrakos1,
M. Hassanain1,2
1Department Of Surgery, McGill University, Montreal, QC;
2Department Of Radiology, McGill University, Montreal,
QC; 3Department Of Surgery, College Of Medicine, King
Saud University, Riyadh, SA; 4Department Of Surgery,
Faculty Of Medicine, King Abdulaziz University, Jeddah,
SA; 5Department Of Oncology, McGill University,
Montreal, QC
Introduction: Treatment strategies for colorectal liver
metastasis (CRCLM) such as major hepatectomy and portal
vein embolization (PVE) rely on the regenerative capacity of
the liver. Neoadjuvant chemotherapy is most often used with
patients undergoing these procedures. We aimed to investi-
gate the effect of neoadjuvant chemotherapy on liver regen-
eration after PVE and after major hepatectomy.
Methods: All CRCLM patients undergoing PVE or major
resection (without PVE) with 3D liver volumetry measure-
ments were included. Liver regeneration (expressed as future
liver remnant (FLR) and percentage of liver regeneration(%
LR)), total liver volume (TLV) and clinical characteristics
were collected from our CRCLM database.
Results: Between 2003–2013, 226 patients were included
(85 major resections, 141 PVE). Mean age was 63 ± 12 years
old and median number of cycles was 6(5–8). In each group,
overall adequate regeneration was observed (+96.5% in FLR
(p < 0.001) post PVE and +45.8% in FLR (p < 0.001) post
resection). In the PVE group, chemotherapy variables did not
show significant association with the amount of liver regen-
eration (number of cycles (p = 0.435), timing (p = 0.563),
chemotherapy agent (p = 0.116)). Similarly in the major
hepatectomy group, neoadjuvant chemotherapy administra-
tion did not show a significant association with %LR
(p = 0.592) or with other treatment variables (number of
cycles, p = 0.114; agent, p = 0.061, timing, p = 0.126). In
both groups, the predicted FLR was inversely correlated with
the % in liver regeneration only (p < 0.001).
Conclusion: Neoadjuvant chemotherapy does not seem to
affect the liver regeneration. The predicted FLR only is
inversely correlating with the amount of LR occurring after
major resection or after PVE.
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LO-E.02 HIGH-DOSE STEREOTACTIC
BODY RADIOTHERAPY (SBRT) FOR
PRIMARY AND METASTATIC
LIVER TUMORS
A. Kirichenko, D. Parda, K. Tom, P. Abrams, J. Oliva,
M. Szramowski, N. Thai
Allegheny Health Network, Pittsburgh, PA
Purpose: SBRT has emerged as an effective non-invasive
radiation therapy to precisely target liver tumors with abla-
tive doses of radiation while avoiding surrounding liver
tissue. We report our single center experience on the efficacy
and tolerability of high-dose SBRT in the management of
inoperable primary and metastatic liver tumors from 2007–
2013.
Patients and Methods: Patients with 1–4 hepatic lesions
and tumor diameter ≤8 cm received liver SBRT of 40–60 Gy
delivered in 4–6 fractions. The primary end point was local
control with at least 8 months of radiographic follow-up, and
secondary end points were toxicity and survival.
Results: 68 patients (79 lesions) completed high-dose liver
SBRT for HCC (31) or oligo-metastases (37). 22 patients
underwent hepatic resections or liver transplant in combina-
tion with SBRT. With median followup 22.5 months (range,
8–67 months) overall survival was 78% for patients with
hepatic oligometastases and 60% in HCC patients (including
11 patients who completed SBRT prior to liver transplant).
No incidence of >grade 2 treatment toxicity or accelerated
MELD score migration was observed. Overall local control
within radiation field at two years after SBRT was 94% and
for lesions with diameter of ≤4 cm was 100%.
Conclusion: In this retrospective analysis we demonstrate
that liver SBRT is safe and effective for the treatment of
hepatic malignancies providing local control rates similar to
hepatic resection.
LO-E.03 THE ROLE OF LYMPHOCYTE
TO NEUTROPHIL RATIO (LNR) AND
PLATELET TO LYMPHOCYTE RATIO
(PLR) AS PROGNOSTIC MARKERS IN
METASTATIC COLORECTAL
CARCINOMA: A REVIEW OF
DATA FROM A RANDOMIZED
CONTROLLED STUDY
P. Philips1, C. R. Scoggins1, R. D. Tomalty2,
M. T. Schreeder3, J. Kaugh4, K. Kim4, W. R. Rilling5,
C. J. Laing6, C. M. Tatum7, L. R. Kelly7,
R. D. Garcia-Monaco8, V. R. Sharma1, R. A. Redman1,
T. S. Crocenzi1, S. M. Strasberg1, R. C. Martin1
1University Of Louisville And James Graham Brown
Cancer Center, Louisville, KY; 2Huntsville Hospital
Interventional Radiology, Huntsville, AL; 3Clearview
Cancer Institute, Huntsville, AL, USA, Huntsville, AL;
4Winship Cancer Institute – Emory University, Atlanta, GA;
5Froedtert Medical College, Milwaukee, WI; 6Radiological
Associates Of Sacramento (RAS), Sacramento, CA; 7Norton
Radiology Associates, Louisville, KY; 8Hospital Italiano,
Buenos Aires, ARGENTIAN
Background: Recent evidence suggests that elevated
neutrophil-lymphocyte ratio(NLR) and platelet-lymphocyte
ratio(PLR) are adverse prognostic markers for survival in
various cancers including colorectal carcinoma.
Methods: Data from a multicenter, prospective-randomized
DEBIRI(Irinotecan-drug eluting beads) study comparing
LC Bead, loaded with irinotecan plus chemotherapy and
bevacizumab versus chemotherapy with bevacizumab in
unresectable metastatic colorectal cancer was analyzed.
Results: There were 30 in the control arm and 41 patients
(112 treatments) in the DEBIRI test arm. The median NLR
and PLR for the whole cohort was 3.41 (range: 1.1–13.9,
IQR: 2.9,4.2) and 187.5 (range: 77–792, IQR: 146.6,227)
respectively. NLR and PLR correlated well with adjusted R2
of 0.825 (p-0.000, F = 128). On univariate analysis, an NLR
>5(median OS 31.9 vs.14.7 months, p = 0.067) and a PLR
>150 (median 31.6 vs. 24 months, p = 0.046) was associated
with decreased overall survival (OS). Other factors associ-
ated with decreased OS were presence of response (CR/PR
or SD) to treatment (16.9 vs. 33.3 months, p0.001), ECOG
score of ≥1 (33.7 vs. 17.4 months, p = 0.006), lung metasta-
sis (18.5 vs. 33.6 months, p = 0.016), history of heart disease
(16.4 vs. 28.7, p = 0.033), albumin <3.5 (10.5 vs. 31.9,
p = 0.001). On multivariate analysis with Cox proportional-
hazards model, only response to treatment was an independ-
ent predictor of decreased OS (hazard ratio = 0.25, 95%CI:
0.06–0.9, p = 0.044).
Conclusion: In this study, response to treatment was the
most important favorable prognostic marker in metastatic
colorectal carcinoma with liver dominant disease. Patients
with high NLR and PLR showed a trend towards worse
prognosis, albeit not independently and needs to be investi-
gated in larger studies.
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LO-E.04 MANAGEMENT AND OUTCOME
OF COLORECTAL CANCER (CRC) LIVER
METASTASES IN THE ELDERLY:
A POPULATION-BASED STUDY
S. Nanji1,2, W. J. Mackillop2,3,4, X. Wei3, C. M. Booth2,3,4
1Department Of Surgery, Queen’s University, Kingston,
ON; 2Department Of Oncology, Queen’s University,
Kingston, ON; 3Department Of Public Health Sciences,
Queen’s University, Kingston, ON; 4Division Of Cancer
Care And Epidemiology, Queens University Cancer
Research Institute, Kingston, ON
Background: Surgical resection is standard treatment for
patients with CRC liver metastases (LM). Limited data
describe practice and outcomes among elderly patients. We
report management and outcomes of surgical resection of
CRC LM in the elderly in routine practice.
Methods: All cases of CRC in Ontario who underwent sur-
gical resection of LM from 1994–2009 were identified using
the population-based Ontario Cancer Registry. We linked
electronic records of treatment to the registry to identify
surgical procedures and utilization of chemotherapy. Pathol-
ogy reports provided details regarding extent of disease and
surgical procedure. Patients were classified as <65, 65–69,
70–74, and ≥75 years of age.
Results: We identified 1310 patients: 710 (54%) <65; 220
(17%) 65–69; 194 (15%) 70–74; and 186 (14%) ≥75 years of
age. Mean number of lesions (2.3, 2.1, 1.8, 1.6, p < 0.0001)
and mean size of the largest lesion (4.0, 4.3, 4.4, 4.5 cm,
p = 0.031) varied across age groups. Elderly patients were
less likely to undergo a major liver resection (≥3 segments):
55%, 17%, 15%, 12%, p = 0.10. Peri-operative chemo-
therapy was used less frequently in the elderly (71%, 63%,
51%, 41%, p < 0.0001). 90-day mortality (2%, 6%, 4%, 8%,
p < 0.001) was greatest among patients ≥75 years of age.
Overall survival at 5 years across the age groups was 49%,
40%, 47%, 28% (p < 0.0001).
Conclusions: Resection of CRC liver metastases is associ-
ated with greater risk of post-operative mortality among
elderly patients despite less aggressive treatment. Although
the long-term outcomes are inferior to younger patients, a
substantial proportion of elderly patients will have long-term
survival.
LO-E.05 FIBROSES PREDICTS SURVIVAL
IN PATIENTS WITH COLORECTAL
LIVER METASTASES RESECTED AFTER
PREOPERATIVE CHEMOTHERAPY
M. C. Marques, H. S. Ribeiro, R. S. De Souza,
W. L. Da Costa, A. L. Diniz, A. L. De Godoy,
I. C. De Farias, M. F. Begnami, R. Chojniak,
V. H. Fonseca, R. S. Bonachi, F. J. Coimbra
A.C. Camargo Cancer Center, Sao Paulo, Brasil
Pathological response to preoperative chemotherapy in
patients with resected colorectal liver metastases has been
identified as one of the most powerful predictors of out-
comes. Fibrosis, necrosis and percentage of viable cells are
recognized as markers of response, but these changes are
also present in liver specimens from patients who didn’t
have preoperative treatment. The aim of this study was to
analyze the incidence of these pathological findings in
patients exposed or not to preoperative treatment and, in the
group of preoperative treatment, identify predictive factors
of pathological response and their impact on survival
results. From 2009 to 2012, ninety patients were analyzed,
and twenty of them did not have preoperative chemotherapy.
Survival analysis only included patients who had preopera-
tive chemotherapy. These patients had higher percentages
of ≥25% fibrosis (p = 0.007) and <50% viable cells
(p = 0.005). With a median follow-up period of 26.5
months, patients who had preoperative treatment and <25%
of fibrosis had a statistically significant worse 3-year overall
survival (96.4 × 59.9%, p = 0.019). In multivariate analyses,
the only independent prognostic factor for overall survival
was ≥25% of fibrosis (HR = 5.5, p = 0.045, 95% CI 1.0–
29.3) and it was correlated with Kras wild type status
(HR = 4.1, p = 0.032, 95% CI 1.1–15.4). No pathologic
findings could predict disease-free survival results. Percent-





IN PATIENTS WITH LIVER
INVOLVEMENT
Y. Berger1, S. Aycart1, P. Tabrizian1, J. Mandeli2, S. Hiotis1,
U. Sarpel1, D. Labow1
1Department Of Surgery, Division Of Surgical Oncology,
Mount Sinai Medical Center, New York, NEW YORK;
2Department Of Preventive Medicine, Mount Sinai School
Of Medicine, New York, NEW YORK
Background: The aim of this study was to examine the
perioperative and long-term results in patients with liver
involvement undergoing cytoreductive surgery and
hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) at
a single tertiary institution.
Methods: Data were obtained from a prospectively col-
lected database maintained between March 2007 and July
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2014. All patients undergoing CRS/HIPEC were divided into
patients who underwent synchronous liver resection (group
1) and those who did not (group 2). Perioperative and long-
term results were compared between the groups.
Results: Out of 269 CRS/HIPEC procedures, group 1
included 103 procedures (38%) performed in 101 patients
with primary diagnoses of colorectal cancer (CRC, 27%),
appendiceal cancer (33%), pseudomyxoma peritonei (13%)
and other malignancies. Most patients (77%) in group 1
underwent stripping of the liver capsule or minor parenchy-
mal resection, whereas 24 patients (23%) underwent paren-
chymal resection of at least one liver segment. Group 1 had
longer duration of surgery (p < 0.001), increased
intraoperative blood loss (p = 0.004), higher number of
organs resected (p < 0.001), longer hospital stay (p = 0.002)
and more ICU admissions (p = 0.02). Major complication
and 90-day mortality rates were not significantly different
between the groups. Median overall survival for CRC
patients in group 1 was poorer (21.8 months, vs. 43.8 months
in group 2, p = 0.01).
Conclusions: CRS/HIPEC procedures with synchronous
liver resection are prolonged, challenging and often require
multivisceral resections in order to achieve optimal
cytoreduction, but are safe even when substantial parenchy-
mal resection is being performed. Liver involvement at the
time of CRS/HIPEC is a marker of poor survival in CRC
patients.
LO-E.07 ACCESS AND SURVIVAL:
A POPULATION-BASED STUDY OF
CURRENT OUTCOMES AFTER HEPATIC
RESECTION IN PATIENTS WITH
METASTATIC COLORECTAL CANCER
V. M. Zaydfudim1, T. L. McMurry2, A. M. Harrigan1,
C. M. Friel1, G. J. Stukenborg2, T. W. Bauer1,
R. B. Adams1, T. L. Hedrick1
1University Of Virginia, Charlottesville, VIRGINIA;
2University Of Virginia, Charlottesville, VIRGINIA
Background: Despite compelling institutional data support-
ing hepatic resection, population-based studies historically
reported underutilization of operative treatment in patients
with colorectal metastases to the liver. The current study
examines trends in hepatic resection and survival among
Medicare recipients with hepatic metastases.
Methods: Medicare recipients with incident colorectal
cancer diagnosed 1991–2009 were identified from the linked
SEER-Medicare dataset. Patients were stratified into histori-
cal control (1991–2001) and current cohort (2002–2009).
Analyses compared rates of hepatectomy and peri-operative
morbidity and mortality. Cox proportional hazards model
tested effects of clinically relevant variables on overall
survival.
Results: Of 31,574 patients with metastatic colorectal
cancer to the liver, 14,925 were in the current cohort treated
after 2002 and 16,649 comprised the historical control group.
The rate of hepatic resection increased from 6.1% pre-2002
to 7.9% currently (p < 0.001). The proportion of patients
treated with major (>3 segments) or minor hepatectomies did
not change (p = 0.345). Peri-operative morbidity including
hemorrhage, infections, or gastrointestinal complications did
not differ (all p > 0.089). 30-day mortality did not differ
between historical controls (4.5%) and current cohort
(3.7%), p = 0.329. After adjusting for significant effects of
age and Charlson comorbidity index (both p < 0.001), both
use of hepatic resection (HR = 0.40, 95%CI: 0.38–0.42,
p < 0.001) and current treatment after 2002 (HR = 0.93,
95%CI: 0.91–0.96, p < 0.001) were associated with
improved overall survival.
Conclusions: Despite statistical significance, clinical
improvement in the rate of hepatic resection from 6.1% to
7.9% is minor. As survival continues to improve, ongoing
efforts should focus on improving access to operative treat-
ment for patients with hepatic metastases.
LO-E.08 SURVIVAL OF PATIENTS AFTER
PORTAL EMBOLIZATION FOR LIVER
METASTASES OF COLORECTAL
CANCER
Y. Collin, R. Huang, M. Plasse, R. Letourneau,
M. Dagenais, S. Turcotte, A. Roy, R. Lapointe,
F. Vandenbroucke-Menu
Centre Hospitalier Universitaire de Montreal, Service de
Chirurgie HBP, Montreal, QC
Introduction: Portal vein embolization (PVE) is an efficient
method used to induce liver hypertrophy in cases of other-
wise unresectable liver tumors, but its impact on survival is
debated. This study compares survival and peri-operative
data between patients resected with prior PVE (group PVE)
and without (group NoPVE).
Methods: This is a prospective study 128 patients with
colorectal liver metastases (CRLM): 71 with PVE and 57
without.
Results: The groups were without significant difference for
age, sex and prior medical history. The PVE group had more
lesions (3.30 VS 2.84; p < 0.001). Within the PVE group,
operative time was longer (221.31 VS 186.54 min; p = 0.01).
There was no statistical difference between the groups for
blood loss (756.25 VS 604.02 mL; p = 0.078). There was no
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difference in complication rates between the groups
(p = 0.465) and there was no peri-operative mortality. Hos-
pital stay was shorter in the PVE group (7.84 VS 8.95 d,
p = 0.038). 5-year overall survival rate and disease free sur-
vival rate were similar between groups (53.2% VS 54.4%;
p = 0.999 and 38.3% VS 40.6%; p = 0.823) Median overall
survival and disease free survival were 65.4 months and 33.6
months respectively, with a median overall follow-up of 39.3
months.
Conclusion: Our results showed similar survival whether
PVE was used or not. Hence, PVE offers a chance for cure
for patients who could not be operated upfront. Moreover,
PVE patients seem to have the same prognosis even with a
larger extent of disease.
LO-E.09 EVALUATING ATTITUDES
TOWARD AND APPLICATION OF
MECHANISMS TO AUGMENT THE
LIVER IN NORTH AND SOUTH
AMERICA (THE MALINSA SURVEY)
R. W. Day, C. Conrad, J. Vauthey, T. A. Aloia
Department Of Surgical Oncology, The University
Of Texas MD Anderson Cancer Center, Houston,
TEXAS
Introduction: Various techniques, including PVE, PVL,
and ALPPS, are being used to augment the future liver
remnant volume in preparation for major hepatectomy. Given
the significant variation between and within these tech-
niques, there is no scientific way to compare their safety and
efficacy.
Purpose: The aim of this study was to survey and document
the availability, variation, utilization and attitudes toward
each of these techniques across high volume HPB centers in
North and South America.
Method: A descriptive 20 question survey was developed
and internally validated with expert review. The survey was
IRB approved and distributed to 42 high volume centers in
Canada, US, Mexico, and South America. Data were col-
lected, collated and analyzed.
Results: Complete surveys were returned from 23 institu-
tions, including representatives from each region (Canada,
US, Mexico, and South America). All of the institutions
responding performed PVE with 5 centers (21.7%) also per-
forming ALPPS procedures. In the previous year, the average
PVE and ALPPS procedures performed were 15.75 and 6.2
per instutition respectively. Only 18 (78.3%) reported the
capability to extend PVE to segment 4, and 12 (52.2%)
reported embolization utilizing embolic microspheres.
Twenty respondents (87%) rated PVE the safest option for
liver hypertrophy; however, 12 respondents (52.2%) believe
the ALPPS procedure is most likely to result in adequate
hypertrophy.
Conclusions: There exists extreme variability in utilization
and attitudes toward the available techniques for FLR volume
augmentation. Penetration of best practice techniques for
PVE is lacking and may contribue toward the attraction of the
riskier ALPPS procedure.
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OP-I.01 T2 GALLBLADDER CANCER –
STILL A NODAL DISEASE
M. R. Sheikh, H. Osman, S. Cheek, S. Hunter,
D. R. Jeyarajah
Methodist Dallas Medical Center, Dallas, TX
Introduction: Treatment of gall bladder cancer (GBC) has
traditionally been viewed with pessimism and lymph node
positivity has been associated with worse prognosis. The aim
of this study is to analyze lymph node positivity in patients
with T2 tumors.
Methods: All patients who underwent surgery for GBC
between September 2005 and June 2014 have been identified
retrospectively in our database. Data collected included clini-
cal presentation, operative findings, and histopathological
data.
Results: Charts of 36 patients were reviewed. 26 patients
had incidental GBC diagnosis following cholecystectomy. 10
patients were T2 on initial cholecystectomy and all under-
went subsequent radical resection. 2 patients from this group
were N1 on initial cholecystectomy and 4 more patients
became N1 on second surgery. Overall 60% patients with T2
disease had node positivity. 2 patients were found to have
residual disease at the liver margin and were upgraded to T3
following resection, one of them also had N1 disease. Overall
50% patients with T2 disease had stage upgrade after radical
resection. 10 patients were diagnosed on imaging. 3 of these
patients were unresectable and 6 were either stage T3 or
higher or node positive.
Conclusions: 60% of T2 GBC were node positive in
our experience. 50% T2 patients found on initial
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